best website for retatrutide President Trump announced that Medicare will cover semaglutide (Wegovy) and tirzepatide (Zepbound) weight management indications for people with obesity. Our senior staff writer Kristen Monaco A pilot program will cover

Le Poole IC, Das PK, van den Wijngaard RM, Bos JD, Westerhof W

The manufacturers now sell direct to cash-pay patients for far less: Zepbound runs $299 to $449 per month through LillyDirect by dose, and Wegovy runs $349 per month for standard doses through NovoCare Pharmacy ($199 per month on the first two fills through December 2026)

If you or someone you know has been affected by PFAS contamination, its crucial to seek legal assistance and hold these companies accountable

GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis

1 As the 2026 patent cliff approaches, the winner will be the one that most effectively uses IP intelligence and proprietary technology to turn the patients home into the center of the clinical world

P53 mutations are highly prevalent in breast tumors [197] potentially granting a survival advantage to breast cancer cells as they navigate mechanically challenging microenvironments